Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual MeetingGlobeNewsWire • 05/20/22
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 InflammationGlobeNewsWire • 05/05/22
Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/03/22
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/03/22
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 04/19/22
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 04/08/22
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/24/22
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/24/22
Kymera Therapeutics to Participate in Upcoming January and February Investor ConferencesGlobeNewsWire • 01/25/22
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of DirectorsGlobeNewsWire • 01/18/22
Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines CompanyGlobeNewsWire • 01/10/22
Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022GlobeNewsWire • 01/04/22
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D DayGlobeNewsWire • 12/16/21
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/13/21
Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical OperationsGlobeNewsWire • 12/06/21
Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D DaySeeking Alpha • 11/30/21
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413GlobeNewsWire • 11/30/21
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingGlobeNewsWire • 11/12/21
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/21